Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes Association meeting in New Orleans.
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.